Antiviral evaluation of N-amino-1,2,3-triazoles against Cantagalo virus replication in cell culture

Potent antiviral activity of brequinar against the emerging Cantagalo virus in cell culture

“…Actions to restrain the spread of the disease have been scarce, and numerous outbreaks have been reported in different states over the last decade [2][3][4]. No specific antiviral therapy is commercially available, encouraging the search for natural and synthetic drugs effective against CTGV replication in vitro [7][8][9]. Here we demonstrate that BQR severely inhibited CTGV production when added during infection, but no direct effect on the infectivity of the virus particles was observed.…”

“…Our group has reported the antiviral activity of several immunosuppressants, such as cyclosporine A (CsA), FK-506 and azathioprine, as well as non-immunosuppressive drugs against the replication of distinct VACV strains, including CTGV [7][8][9][10][11][12]. Brequinar (BQR) is an immunosuppressive and antiproliferative drug effective against allograft and xenograft rejection following transplantation [13,14].…”

Synthesis of Isoxazole and 1,2,3-Triazole Isoindole Derivatives via Silver- and Copper-Catalyzed 1,3-Dipolar Cycloaddition Reaction

“…The aim of this present work focuses on the synthesis of N-heterocyclic compounds, namely the synthesis of substituted isoxazole and triazole derivatives, since an important number of compounds containing the isoxazole and the triazole scaffold are known to exhibit a variety of biological activities in the pharmaceutical [16] and medicinal areas [17]. Representative examples of synthetic drugs incorporating these motifs are Tazobactam I [18][19][20][21][22], Rufinamide II [23][24][25], phenylisoxazole derivatives III [26,27], and Bextra (Valdecoxib) IV [28][29][30].…”

“…Tazobactam I [18][19][20][21][22], Rufinamide II [23][24][25], phenylisoxazole derivatives III [26,27], and Bextra (Valdecoxib) IV [28][29][30].…”

Crystal Structures of 2-Phenyl-2H-1,2,3-Triazol-4-Carbaldehyde, an Active α-Glycosidase Inhibition Agent, and (1-Phenyl-1H-1,2,3-Triazol-4-yl)Methyl Benzoate and (2-(4-Fluorophenyl)-2H-1,2,3-Triazole-4-yl)Methanol, Two Moderately Active Compounds

“…Compound 1a crystallizes in the monoclinic space group P2 1 with a = 4.5661(5), b = 10.5573 (14), c = 13.9694 (19) Graphical Abstract The relatively flat compounds, (2-(4-fluorophenyl)-2H-1,2,3-triazole-4-yl)methanol and 2-phenyl-2H-1,2,3-triazol-4-carbaldehyde, contrast with compound (1-phenyl-1H-1,2,3-triazol-4-yl)methyl benzoate, which is ''V'' shaped, with a dihedral angle between the near planar phenyltriazolyl-CH2 and phenyl-CO2CH2 moieties of 88.11 (4) [1][2][3], in particular for their biological activities, which include as antiviral [4][5][6], antimalarial [7], antitubercular [8][9][10], antifungal [11,12] anti-HIV [13], b-lactamase inhibition [14], anti-epileptic [15], anti-HSV [16], anti-inflammatory [17], antimicrobial [18,19] and a-glycosidase inhibition agents [20][21][22][23]. Patents lodged in the period 2008-2011 for 1H-1,2,3-triazole and 2H-1,2,3-triazole derivatives have been included in a general survey for all triazolyl compounds [24].…”